Cargando…

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020

Global analysis of the susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) and the polymerase acidic (PA) inhibitor (PAI) baloxavir was conducted by five World Health Organization Collaborating Centres for Reference and Research on Influenza during two periods (May 2018–May 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Govorkova, Elena A., Takashita, Emi, Daniels, Rod S., Fujisaki, Seiichiro, Presser, Lance D., Patel, Mira C., Huang, Weijuan, Lackenby, Angie, Nguyen, Ha T., Pereyaslov, Dmitriy, Rattigan, Aine, Brown, Sook Kwan, Samaan, Magdi, Subbarao, Kanta, Wong, Sun, Wang, Dayan, Webby, Richard J., Yen, Hui-Ling, Zhang, Wenqing, Meijer, Adam, Gubareva, Larisa V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254721/ https://www.ncbi.nlm.nih.gov/pubmed/35292289 http://dx.doi.org/10.1016/j.antiviral.2022.105281

Ejemplares similares

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
por: Takashita, Emi, et al.
Publicado: (2018)

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014
por: Takashita, Emi, et al.
Publicado: (2015)

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016
por: Gubareva, Larisa V., et al.
Publicado: (2017)

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017
por: Lackenby, Angie, et al.
Publicado: (2018)

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015
por: Hurt, Aeron C., et al.
Publicado: (2016)

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013
por: Meijer, Adam, et al.
Publicado: (2014)

Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
por: Takashita, Emi, et al.
Publicado: (2019)

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
por: Fukao, Keita, et al.
Publicado: (2019)

The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice
por: Yoshii, Naoko, et al.
Publicado: (2020)

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018)

The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor
por: Todd, Brendan, et al.
Publicado: (2021)

Characterization of neuraminidase inhibitor‐resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post‐pandemic periods in Japan
por: Takashita, Emi, et al.
Publicado: (2013)

Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010–2015
por: Tewawong, Nipaporn, et al.
Publicado: (2018)

Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil
por: Nakauchi, Mina, et al.
Publicado: (2020)

Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study
por: Komeda, Takuji, et al.
Publicado: (2020)

Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
por: Taniguchi, Keiichi, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection
por: Ando, Yoshinori, et al.
Publicado: (2020)

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019
por: Takashita, Emi, et al.
Publicado: (2019)

Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors
por: Jones, Jeremy C., et al.
Publicado: (2018)

Synergistic Antiviral Activity of S-033188/S-033447, a Novel Inhibitor of Influenza Virus Cap-Dependent Endonuclease, in Combination with Neuraminidase Inhibitors In Vitro
por: Kitano, Mitsutaka, et al.
Publicado: (2017)

Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019
por: Takashita, Emi, et al.
Publicado: (2019)

Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report
por: Harada, Naonori, et al.
Publicado: (2020)

Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model
por: Koszalka, Paulina, et al.
Publicado: (2022)

Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models
por: Fukao, Keita, et al.
Publicado: (2019)

Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance–Associated Substitutions in Ferrets
por: Pascua, Philippe Noriel Q., et al.
Publicado: (2016)

Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design
por: Zhu, Qinchang, et al.
Publicado: (2015)

Author Correction for Jones et al., “Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors”
por: Jones, Jeremy C., et al.
Publicado: (2018)

Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective
por: Okomo-Adhiambo, Margaret, et al.
Publicado: (2010)

A community cluster of influenza A(H3N2) virus infection with reduced susceptibility to baloxavir due to a PA E199G substitution in Japan, February to March 2023
por: Takashita, Emi, et al.
Publicado: (2023)

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
por: Mishin, Vasiliy P., et al.
Publicado: (2019)

Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan
por: Chong, Yong, et al.
Publicado: (2019)

Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil
por: Yoshino, Ryunosuke, et al.
Publicado: (2019)

In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses
por: Checkmahomed, Liva, et al.
Publicado: (2020)

Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season
por: Okomo‐Adhiambo, Margaret, et al.
Publicado: (2013)

Structural and Biochemical Basis for Development of Influenza Virus Inhibitors Targeting the PA Endonuclease
por: DuBois, Rebecca M., et al.
Publicado: (2012)

Inhibition of Neuraminidase Inhibitor-Resistant Influenza Virus by DAS181, a Novel Sialidase Fusion Protein
por: Triana-Baltzer, Gallen B., et al.
Publicado: (2009)

1536. Population Pharmacokinetic Analysis of Baloxavir Morboxil, a Cap-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications
por: Koshimichi, Hiroki, et al.
Publicado: (2019)

Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts
por: Tang, Jing, et al.
Publicado: (2019)

Bacterial Neuraminidase Rescues Influenza Virus Replication from Inhibition by a Neuraminidase Inhibitor
por: Nishikawa, Tomoko, et al.
Publicado: (2012)

Systematic review of influenza resistance to the neuraminidase inhibitors
por: Thorlund, Kristian, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e358vrddme9p09m0lbmuu6j2mi